DUniversidad &amperio;IncluSion enRinvestigaciontunderpinningPAGprevención &amperio;Tensayos de terapia

Breast cancer is a type of cancer that starts in the breast. When the cancer has spread to nearby lymph nodes, it is called node-positive breast cancer. HER2-negative means the cancer cells do not have a lot of a certain protein called HER2.

In this clinical trial, doctors are testing different ways of treating node-positive, HER2-negative breast cancer before surgery. The treatment will include chemotherapy, which is a medicine that kills cancer cells, and pembrolizumab, which is a type of immunotherapy that helps the body's immune system fight cancer.

The trial is called P-RAD because it will also test different doses of radiation therapy. Radiation therapy uses high-energy rays to kill cancer cells. The different doses of radiation are called no radiation, low dose radiation, and high dose radiation.

The goal of the trial is to see which treatment plan is the most effective in treating node-positive, HER2-negative breast cancer before surgery. The results of this trial will help doctors to better understand the benefits and potential side effects of different treatment options for this type of breast cancer.

This is a study that will test a new treatment for premenopausal women with a certain type of breast cancer. The cancer cells have hormone receptors and do not have a protein called HER2. The treatment combines a medicine called TOL2506 with another treatment called endocrine therapy. TOL2506 is a type of medicine that can stop the ovaries from making hormones. The study will see if using TOL2506 along with endocrine therapy can help stop the cancer from growing. The study will be done with premenopausal women who have already been diagnosed with this type of breast cancer.

This clinical trial aims to help patients with breast cancer make better decisions about their treatment by improving the way doctors communicate with them. Researchers will test a tool called a Shared Decision Engagement System (SHARES) that can help patients and doctors talk about treatment options in a way that is easier to understand. By using this tool, patients may feel more involved in their care and better able to make decisions that are right for them. The trial will compare patients who use the tool to those who do not, to see if it improves the communication and decision-making process.

Breast cancer is a disease where cells in the breast grow too much and can spread to other parts of the body. There are different types of breast cancer, and one type is called HER-2 positive breast cancer. This means that the cancer cells have a lot of something called HER-2 receptors, which are like little doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other types of breast cancer, but they also respond well to certain drugs. HER2CLIMB-05 is a clinical trial that aims to evaluate the effectiveness of tucatinib in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2-positive breast cancer. The study is a randomized, double-blind, phase 3 trial, meaning that patients will be assigned to receive either tucatinib or a placebo (an inactive substance) in addition to trastuzumab and pertuzumab, and neither the patients nor the researchers will know which treatment the patient is receiving. The goal of the study is to determine whether tucatinib can improve the outcomes of patients with metastatic HER2-positive breast cancer.

The ZEST study is a clinical trial that will compare a drug called niraparib to a placebo in people with HER2-negative breast cancer that either has a BRCA gene mutation or is triple-negative. The trial will focus on people who still have signs of the cancer in their blood after receiving standard treatment. Niraparib is a type of drug called a PARP inhibitor, which can help prevent cancer cells from repairing their DNA and dividing. The study aims to see if niraparib is effective in treating this type of breast cancer and if it is safe to use.

The EMBER-3 study is a medical research study that will compare the effectiveness and safety of a new drug called LY3484356 to the usual hormone therapy for patients with advanced or metastatic breast cancer that is positive for estrogen but negative for HER2. The study will be conducted in patients who have already received hormone therapy but their cancer has continued to grow. The study will be randomized, which means that patients will be assigned randomly to receive either LY3484356 or their doctor's choice of hormone therapy. The study will be open-label, which means that both the patients and the doctors will know which treatment the patient is receiving. The goal of the study is to determine if LY3484356 can provide better outcomes than the current standard of care in this patient population.

FLAMINGO-01 is a clinical trial aimed at evaluating a new treatment called GLSI-100 in people with HER2/neu positive breast cancer. The study will include participants who have residual disease or high-risk PCR after receiving neoadjuvant and postoperative adjuvant trastuzumab-based therapy. GLSI-100 is a combination of two substances called GP2 and GM-CSF that work to stimulate the body's immune system to fight cancer cells. The study will compare the effectiveness and safety of GLSI-100 to a placebo (an inactive substance).

This study is looking at a new tool called PD G 506 A and a special imaging system called the Eagle V1.2 to help doctors see cancer cells during breast conserving surgery. This tool and imaging system may help doctors remove all the cancer cells while saving as much healthy breast tissue as possible. The study will be done at multiple hospitals to see if this new tool and imaging system work well for patients having this type of surgery.

The COMET trial is a research study that compares two different approaches to treating a type of breast cancer called DCIS (ductal carcinoma in situ). One approach is to have surgery to remove the abnormal cells, followed by monitoring without any further treatment. The other approach is to have monitoring without surgery, but with the option to take medication called endocrine therapy. The trial will randomly assign participants to one of these two approaches and will track their progress over time to determine which approach is more effective and safe for treating low-risk DCIS.

In this study, researchers are testing a drug called ruxolitinib in patients with high risk and premalignant (not yet cancerous) breast conditions. Ruxolitinib is a drug that targets a specific pathway involved in inflammation and cell growth, which could potentially prevent the development of breast cancer. The study is a randomized phase II trial, meaning that patients will be randomly assigned to receive either ruxolitinib or a placebo (an inactive substance) before they undergo surgery to remove breast tissue. This is called a "window-of-opportunity" trial because the drug is given during the time between the diagnosis of the high-risk or premalignant condition and the surgery, allowing researchers to study its effects on breast tissue. The goal of the study is to see if ruxolitinib can reduce the number of precancerous cells in the breast tissue and ultimately prevent the development of breast cancer.

In this study, doctors will use pictures of your body (called imaging) and look at your genes (the parts of your body that determine how you look and work) to see if they can predict how well you will respond to treatment. They will take pictures and samples of your cancer at different times during treatment to see if they can see changes that show if the treatment is working or not. This study is called "Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2."

Breast cancer is a disease where cells in the breast grow too much and can spread to other parts of the body. Hormone receptor positive breast cancer is a type of breast cancer that grows in response to the hormone estrogen. Metastatic breast cancer means that the cancer has spread to other parts of the body. In this clinical trial, doctors are testing a new treatment for hormone receptor positive metastatic breast cancer. The treatment is a combination of exercise and first-line therapy. First-line therapy is the first type of treatment that is given to a patient with metastatic breast cancer. The trial is divided into two parts, called Phase 1a and 1b. In Phase 1a, doctors will test the safety of the exercise treatment and make sure that it does not cause any harmful side effects when given with first-line therapy. They will also determine the best dose of exercise for patients to receive. In Phase 1b, doctors will test how well the exercise treatment works when given with first-line therapy. The exercise treatment will include activities like walking, cycling, and resistance training. These activities will be done under the supervision of trained exercise specialists. The goal of the exercise treatment is to improve the patient's overall health and well-being, and potentially improve the effectiveness of the first-line therapy. The results of this trial will help doctors to better understand the benefits and potential side effects of exercise treatment in combination with first-line therapy for hormone receptor positive metastatic breast cancer.